These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 15564515)

  • 1. Genetic screen for monitoring severe acute respiratory syndrome coronavirus 3C-like protease.
    Parera M; Clotet B; Martinez MA
    J Virol; 2004 Dec; 78(24):14057-61. PubMed ID: 15564515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic screen for monitoring hepatitis C virus NS3 serine protease activity.
    Martinez MA; Clotet B
    Antimicrob Agents Chemother; 2003 May; 47(5):1760-5. PubMed ID: 12709356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The newly emerged SARS-like coronavirus HCoV-EMC also has an "Achilles' heel": current effective inhibitor targeting a 3C-like protease.
    Ren Z; Yan L; Zhang N; Guo Y; Yang C; Lou Z; Rao Z
    Protein Cell; 2013 Apr; 4(4):248-50. PubMed ID: 23549610
    [No Abstract]   [Full Text] [Related]  

  • 4. Autoprocessing mechanism of severe acute respiratory syndrome coronavirus 3C-like protease (SARS-CoV 3CLpro) from its polyproteins.
    Muramatsu T; Kim YT; Nishii W; Terada T; Shirouzu M; Yokoyama S
    FEBS J; 2013 May; 280(9):2002-13. PubMed ID: 23452147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of peptide-aldehyde inhibitors using R188I mutant of SARS 3CL protease as a proteolysis-resistant mutant.
    Akaji K; Konno H; Onozuka M; Makino A; Saito H; Nosaka K
    Bioorg Med Chem; 2008 Nov; 16(21):9400-8. PubMed ID: 18845442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isatin compounds as noncovalent SARS coronavirus 3C-like protease inhibitors.
    Zhou L; Liu Y; Zhang W; Wei P; Huang C; Pei J; Yuan Y; Lai L
    J Med Chem; 2006 Jun; 49(12):3440-3. PubMed ID: 16759084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds.
    Báez-Santos YM; St John SE; Mesecar AD
    Antiviral Res; 2015 Mar; 115():21-38. PubMed ID: 25554382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating the 3C-like protease activity of SARS-Coronavirus: recommendations for standardized assays for drug discovery.
    Grum-Tokars V; Ratia K; Begaye A; Baker SC; Mesecar AD
    Virus Res; 2008 Apr; 133(1):63-73. PubMed ID: 17397958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peptide aldehyde inhibitors challenge the substrate specificity of the SARS-coronavirus main protease.
    Zhu L; George S; Schmidt MF; Al-Gharabli SI; Rademann J; Hilgenfeld R
    Antiviral Res; 2011 Nov; 92(2):204-12. PubMed ID: 21854807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation and maturation of SARS-CoV main protease.
    Xia B; Kang X
    Protein Cell; 2011 Apr; 2(4):282-90. PubMed ID: 21533772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The papain-like protease determines a virulence trait that varies among members of the SARS-coronavirus species.
    Niemeyer D; Mösbauer K; Klein EM; Sieberg A; Mettelman RC; Mielech AM; Dijkman R; Baker SC; Drosten C; Müller MA
    PLoS Pathog; 2018 Sep; 14(9):e1007296. PubMed ID: 30248143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The catalysis of the SARS 3C-like protease is under extensive regulation by its extra domain.
    Shi J; Song J
    FEBS J; 2006 Mar; 273(5):1035-45. PubMed ID: 16478476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chimeric coronavirus-like particles carrying severe acute respiratory syndrome coronavirus (SCoV) S protein protect mice against challenge with SCoV.
    Lokugamage KG; Yoshikawa-Iwata N; Ito N; Watts DM; Wyde PR; Wang N; Newman P; Kent Tseng CT; Peters CJ; Makino S
    Vaccine; 2008 Feb; 26(6):797-808. PubMed ID: 18191004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis, and bioevaluation of viral 3C and 3C-like protease inhibitors.
    Prior AM; Kim Y; Weerasekara S; Moroze M; Alliston KR; Uy RA; Groutas WC; Chang KO; Hua DH
    Bioorg Med Chem Lett; 2013 Dec; 23(23):6317-20. PubMed ID: 24125888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanism for controlling the dimer-monomer switch and coupling dimerization to catalysis of the severe acute respiratory syndrome coronavirus 3C-like protease.
    Shi J; Sivaraman J; Song J
    J Virol; 2008 May; 82(9):4620-9. PubMed ID: 18305031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and Evaluation of Anti-SARS-Coronavirus Agents Based on Molecular Interactions with the Viral Protease.
    Akaji K; Konno H
    Molecules; 2020 Aug; 25(17):. PubMed ID: 32867349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two adjacent mutations on the dimer interface of SARS coronavirus 3C-like protease cause different conformational changes in crystal structure.
    Hu T; Zhang Y; Li L; Wang K; Chen S; Chen J; Ding J; Jiang H; Shen X
    Virology; 2009 Jun; 388(2):324-34. PubMed ID: 19409595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutation of Gly-11 on the dimer interface results in the complete crystallographic dimer dissociation of severe acute respiratory syndrome coronavirus 3C-like protease: crystal structure with molecular dynamics simulations.
    Chen S; Hu T; Zhang J; Chen J; Chen K; Ding J; Jiang H; Shen X
    J Biol Chem; 2008 Jan; 283(1):554-564. PubMed ID: 17977841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis, and evaluation of trifluoromethyl ketones as inhibitors of SARS-CoV 3CL protease.
    Shao YM; Yang WB; Kuo TH; Tsai KC; Lin CH; Yang AS; Liang PH; Wong CH
    Bioorg Med Chem; 2008 Apr; 16(8):4652-60. PubMed ID: 18329272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Severe acute respiratory syndrome coronavirus 3C-like protease-induced apoptosis.
    Lin CW; Lin KH; Hsieh TH; Shiu SY; Li JY
    FEMS Immunol Med Microbiol; 2006 Apr; 46(3):375-80. PubMed ID: 16553810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.